13F Holdings
中文EN

USAQ QHSLab, Inc.

Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 856984 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY13.1%
TTM net income YoY213.1%
TTM EPS YoY150.0%
Revenue 3-yr CAGR29.5%
Net income 3-yr CAGR—

Margins

Gross margin68.2%
Operating margin-2.2%
Net margin14.8%
FCF margin—
EBITDA margin0.3%

Returns

ROE97.8%
ROA25.1%
ROIC (approx.)-23.4%
Asset turnover1.70x

Leverage & solvency

Liabilities / assets14.1%
Debt / equity0.00x
Current ratio2.10x
Interest coverage-1.03x

Cash quality & payout

Operating cash flow / net income-0.54x
Accruals ratio38.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$2.69M$2.13M$1.41M$1.24M$1.41M
Cost of revenue$880,892$774,036$615,388$623,667$743,673
Gross profit$1.81M$1.36M$793,607$619,519$670,748
R&D expense$484,873$294,479$214,008$190,117$90,874
SG&A expense$439,143$276,496$259,108$387,512$454,008
Operating income$131,244$205,738-$240,158-$560,539-$502,258
Interest expense$237,413$465,055$230,494$433,442$246,490
Pretax income$457,417-$259,239-$468,362-$996,001-$770,176
Net income$457,417-$259,239-$468,362-$996,001-$770,176
EBITDA$221,972$352,313-$93,583-$432,580-$466,202
EPS (basic)0.04-0.03-0.05-0.11-0.10
EPS (diluted)0.02-0.03-0.05-0.11-0.10
Weighted avg. shares (diluted)19.34M10.29M9.42M9.00M7.86M
Balance sheet
Cash & equivalents$636,157$157,168$51,582$178,694$286,855
Receivables$190,610$196,089$71,382$47,734$70,474
Inventory$35,790$41,779$25,181$51,840$65,740
Current assets$883,009$420,827$156,132$285,578$445,782
Intangibles$1.29M$1.36M$1.43M$1.50M$1.58M
Total assets$2.17M$1.80M$1.68M$1.96M$2.21M
Current liabilities$449,860$2.41M$2.06M$1.71M$874,954
Short-term debt——$546,052$342,391$253,865
Long-term debt$90,704————
Total debt$90,704————
Total liabilities$546,078$2.41M$2.06M$1.88M$1.38M
Shareholders' equity$1.62M-$607,756-$375,617$76,245$824,066
Net debt-$545,453————
Shares outstanding15.03M10.81M9.74M9.32M8.76M
Cash flow statement
Operating cash flow$178,118$142,437-$159,627-$350,994-$354,738
Investing cash flow———-$37,119-$154,571
Financing cash flow$300,871-$36,851$32,515$279,952$701,822
Depreciation & amortization$90,728$146,575$146,575$127,959$36,056
Stock-based compensation$0$0$6,000$30,084$35,683

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.